Novasenta, a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, announced the completion of $40 million in Series A financing led by UPMC Enterprises.

Founded in 2018, Novasenta is focused on the discovery of novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. The company has developed a proprietary platform for single-cell RNA based analysis of high-quality, human tumor samples and combined it with its advanced data mining and target validating abilities to accelerate the path from discovery to drug development.